| __timestamp | Neurocrine Biosciences, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 1860000 |
| Thursday, January 1, 2015 | 32480000 | 2963000 |
| Friday, January 1, 2016 | 68081000 | 6961000 |
| Sunday, January 1, 2017 | 169906000 | 11779000 |
| Monday, January 1, 2018 | 248932000 | 13697000 |
| Tuesday, January 1, 2019 | 354100000 | 15749000 |
| Wednesday, January 1, 2020 | 433300000 | 18638000 |
| Friday, January 1, 2021 | 583300000 | 27196000 |
| Saturday, January 1, 2022 | 752700000 | 31739000 |
| Sunday, January 1, 2023 | 887600000 | 33491000 |
| Monday, January 1, 2024 | 1007200000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Protagonist Therapeutics, Inc. over the past decade. Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing from approximately $18 million in 2014 to nearly $888 million in 2023. This represents a growth of nearly 4,800%, reflecting the company's aggressive expansion and investment in administrative capabilities.
Conversely, Protagonist Therapeutics, Inc. has maintained a more modest growth trajectory, with SG&A expenses rising from about $1.9 million in 2014 to $33 million in 2023, marking an increase of over 1,600%. This difference highlights the varied strategic approaches of these companies in managing their operational costs. As the biotech industry continues to evolve, understanding these financial trends is essential for investors and stakeholders.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
PTC Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: MorphoSys AG vs Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Celldex Therapeutics, Inc.